ethyl 3-(aminocarbonyl)-4-{[3-(methyloxy)phenyl]amino}-6-quinolinecarboxylate | 849126-91-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ethyl 3-(aminocarbonyl)-4-{[3-(methyloxy)phenyl]amino}-6-quinolinecarboxylate
• 英文别名: Ethyl 3-carbamoyl-4-(3-methoxyanilino)quinoline-6-carboxylate
• CAS: 849126-91-6
• 化学式: C₂₀H₁₉N₃O₄
• 分子量: 365.389
• InChiKey: HXGVUPSIGTWLGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 3-(aminocarbonyl)-4-{[3-(methyloxy)phenyl]amino}-6-quinolinecarboxylate 在 sodium hydroxide 、 乙醇 、 水 作用下， 反应 16.0h， 生成 3-(aminocarbonyl)-4-{[3-(methyloxy)phenyl]amino}-6-quinolinecarboxylic acid
  参考文献：
  名称：

  [EN] DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION
  [FR] DERIVES DE 3-AMINOCARBONYLQUINOLINE, COMPOSITIONS PHARMACEUTIQUES CONTENANT CES DERIVES ET PROCEDES ET INTERMEDIAIRES SERVANT A LEUR PREPARATION

  摘要：

  公式(I)的化合物或其药学上可接受的盐是磷酸二酯酶IV型（PDE4）的抑制剂，并可用于治疗炎症和/或过敏性疾病。

  公开号：

  WO2005030725A1
• 作为产物：
  描述：

  6-Iodo-4-(3-methoxyanilino)quinoline-3-carboxamide 、 乙醇 、 一氧化碳 在 bis-triphenylphosphine-palladium(II) chloride 、 三乙胺 作用下， 生成 ethyl 3-(aminocarbonyl)-4-{[3-(methyloxy)phenyl]amino}-6-quinolinecarboxylate
  参考文献：
  名称：

  Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration

  摘要：

  Crystallography driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of quinoline-3-carboxamides as highly potent and selective inhibitors of phosphodiesterase 4B. This series has been optimized to GSK256066, a potent PDE4B inhibitor which also inhibits LPS induced production of TNF-alpha from isolated human peripheral blood mononuclear cells with a pIC(50) of 11.1. GSK256066 also has a suitable pro. le for inhaled dosing. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.04.012

文献信息

• [EN] DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION<br/>[FR] DERIVES DE 3-AMINOCARBONYLQUINOLINE, COMPOSITIONS PHARMACEUTIQUES CONTENANT CES DERIVES ET PROCEDES ET INTERMEDIAIRES SERVANT A LEUR PREPARATION
  申请人：GLAXO GROUP LTD

  公开号：WO2005030725A1

  公开（公告）日：2005-04-07

  Compounds of formula (I) or pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type IV (PDE4) and are of use in the treatment of inflammatory and/or allergic diseases.

  公式(I)的化合物或其药学上可接受的盐是磷酸二酯酶IV型（PDE4）的抑制剂，并可用于治疗炎症和/或过敏性疾病。
• Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation
  申请人：Edlin Christopher

  公开号：US20070191426A1

  公开（公告）日：2007-08-16

  Compounds of formula (I) or pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type IV (PDE4) and are of use in the treatment of inflammatory and/or allergic diseases.

  化合物I式或其药学上可接受的盐是磷酸二酯酶IV型（PDE4）的抑制剂，可用于治疗炎症和/或过敏性疾病。
• DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION
  申请人：GLAXO GROUP LIMITED

  公开号：EP1673345A1

  公开（公告）日：2006-06-28
• Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration
  作者：Michael D. Woodrow、Stuart P. Ballantine、Michael D. Barker、Beth J. Clarke、John Dawson、Tony W. Dean、Christopher J. Delves、Brian Evans、Sharon L. Gough、Steven B. Guntrip、Stuart Holman、Duncan S. Holmes、Michael Kranz、Mika K. Lindvaal、Fiona S. Lucas、Margarete Neu、Lisa E. Ranshaw、Yemisi E. Solanke、Don O. Somers、Peter Ward、Joanne O. Wiseman

  DOI：10.1016/j.bmcl.2009.04.012

  日期：2009.9

  Crystallography driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of quinoline-3-carboxamides as highly potent and selective inhibitors of phosphodiesterase 4B. This series has been optimized to GSK256066, a potent PDE4B inhibitor which also inhibits LPS induced production of TNF-alpha from isolated human peripheral blood mononuclear cells with a pIC(50) of 11.1. GSK256066 also has a suitable pro. le for inhaled dosing. (C) 2009 Elsevier Ltd. All rights reserved.